A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

Inclusion Criteria:

- Subjects must give a written, signed and dated informed consent

- Chronic atopic dermatitis present for at least 1 year before Baseline

- Moderate to severe atopic dermatitis defined as per EASI, IGA and BSA.

- Documented recent history (within 6 months before the screening visit) of inadequate
response to treatment with topical medications or for whom topical treatments are
otherwise medically inadvisable

- Candidate for systemic treatment

Exclusion Criteria:

- Any skin disease that would confound the diagnosis or evaluation of atopic dermatitis
disease activity

- Use of other investigational drugs within 5 half-lives of enrollment, or within 30
days or until the expected pharmacodynamic effect has returned to baseline, whichever
is longer.

- History of hypersensitivity to any of the study drug constituents or to drugs of
similar chemical classes.

- Participation in prior ZPL389 studies